Free Biopharma Stock Content

(Updated version 8/16/22) Bull thesis: The bull thesis on KPTI remains that the stock trades at a discount for a company with a promising...

BCRX is a commercial stage company that focuses on difficult to develop oral therapies for rare disease with a productive drug...

(Updated 4/26/22) BULL THESIS NKTR overall corporate A leader in the development of cytokine-based therapies Lead asset, NKTR358...

(Updated on 3/24/22 based on quarterly report) BULL THESIS ICPT overall corporate and executive summary Approved drug Ocaliva (OCA) for...

$XBI $89.59 | -1.96% Covid Updates $MRNA +1.6% Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster...

$XBI $91.38 | -0.80% Covid Updates $VALN +6.5% Valneva Advances Booster Phase of Cov-Compare Trial of Its Inactivated COVID-19 Vaccine...

$XBI $92.11 | +2.31% Covid Updates $SRNE -7.1% Sorrento Receives Purchase Order for 10 Million Covistix Tests From Its Subsidiary...

$XBI $90.03 | -2.1% Covid Updates $GILD +1.0% FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High...

$XBI $91.70 | -1.64% Covid Updates $ Pipeline Updates $PRVB -1.8% Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study...

$XBI $93.50 | -1.08% Covid Updates $NVAX -6.2% Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for...

Summary The American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) takes place from January 20-22, 2022 and...

$XBI $94.52 | -5.94% Covid Updates $SRNE -7.2% Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Clinical Trial...

$XBI $100.49 | +2.44% d Covid Updates $RDHL +2.9% RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase...

$XBI $98.10 -2.5% Covid Updates $RDHL -1.6% RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study...

$XBI $100.60 -3.2% Covid Updates $OCGN +0.24 COVAXIN™ (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2...

$XBI $103.89 0.73% % Covid Updates $TNXP +1.7% Tonix Pharmaceuticals Initiates Enrollment in Clinical Trial of TNX-2100, a Diagnostic...

$XBI $103.14 +0.2% % Covid Updates $NVAX +6.5% Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax'...

SUMMARY 2021 was a tough year for public small and mid-cap biotech XBI down 20% (vs. IBB +~1% vs. Russell2000 +~14% vs. S&P500 +~27%)...

$XBI $102.99 | -2.1% % Pipeline Updates $IOVA +1.4% Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell...

$XBI $105.20 -0.03% % Covid Updates $COCP -3.1% Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19...